SCHEMBL5660422

SCHEMBL5660422

CCCC(O)c1cccc2c1CNC2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.46
PIM1 P11309 3/20 0.46
ROCK1 Q13464 3/20 0.46
CDK5 Q00535 2/20 0.46
DYRK1A Q13627 2/20 0.46
CSNK1A1 P48729 1/20 0.46
LRRK2 Q5S007 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
LTK P29376 1/20 0.41
MST1R Q04912 1/20 0.41
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
KDR P35968 8/20 0.40
PARP1 P09874 2/20 0.38
PARP10 Q53GL7 1/20 0.38
PARP11 Q9NR21 1/20 0.38
ROCK2 O75116 2/20 0.37
MAP4K4 O95819 2/20 0.37
LCK P06239 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5661834 0.94 CLK4 (0.41) CLK4PIM1ROCK1CDK5DYRK1A
SCHEMBL9910069 0.77 CLK4 (0.56) CLK4PIM1ROCK1CDK5DYRK1A
SCHEMBL6297546 0.77 CDK5 (0.49) CLK4PIM1ROCK1CDK5DYRK1A
SCHEMBL32686638 0.73 CDK5 (0.56) CLK4PIM1ROCK1CDK5DYRK1A
SCHEMBL12219092 0.72 CDK5 (0.58) CLK4PIM1ROCK1CDK5DYRK1A
SCHEMBL28860690 0.70 CLK4 (0.51) CLK4PIM1ROCK1CDK5DYRK1A
SCHEMBL6297545 0.69 PARP1 (0.70) CLK4PIM1ROCK1CDK5DYRK1A
SCHEMBL29532218 0.69 PARP1 (0.70) CLK4PIM1ROCK1CDK5DYRK1A
SCHEMBL28224570 0.68 CLK4 (0.53) CLK4PIM1ROCK1CDK5DYRK1A
SCHEMBL24142865 0.68 CDK5 (0.61) CLK4PIM1ROCK1CDK5DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166617-B2 Cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-01-23 US disclosed
US-20030212094-A1 Novel cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2003-11-13 US disclosed
EP-1260512-A1 NOVEL CYCLIC AMIDE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2002-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212094-A1 Novel cyclic amide derivatives SIGMAR1, OPRM1, OPRD1 CLK4 3533/4885PIM1 2678/4885ROCK1 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.